Skip to main content
锦波生物 logo

锦波生物 — Investor Relations & Filings

Ticker · 920982 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 391 across all filing types
Latest filing 2025-11-11 Capital/Financing Update
Country CN China
Listing Beijing Stock Exchange 920982

About 锦波生物

https://www.sxjbswyy.com/

Shanxi Jinbo Bio-Pharmaceutical Co., Ltd. specializes in the research, development, and manufacturing of functional proteins through synthetic biology. The company is recognized for its industrialization of recombinant humanized collagen, specifically Type III collagen with a stable triple helix structure. Its core business encompasses the production of medical-grade biomaterials, functional skincare products, and medical devices used in aesthetics, wound healing, and gynecological health. By utilizing advanced protein engineering, the company provides biocompatible solutions designed for tissue repair and anti-aging applications. Its technical focus remains on the structural optimization and large-scale production of high-purity recombinant proteins to meet clinical and consumer health demands.

Recent filings

Filing Released Lang Actions
中信证券股份有限公司关于锦波生物向特定对象发行股票之上市保荐书
Capital/Financing Update Classification · 95% confidence The document is titled as a "上市保荐书" which translates to "Listing Sponsorship Letter" or "Sponsorship Document for Stock Issuance to Specific Objects". It is issued by a securities company (中信证券股份有限公司) acting as the sponsor for 山西锦波生物医药股份有限公司's issuance of shares to specific investors. The content includes detailed information about the issuer, the issuance plan, pricing, number of shares, use of proceeds, risk factors, and compliance with regulatory requirements. It is a comprehensive document related to a capital raising event through a private placement or directed share issuance. This type of document is not a financial report like an annual or interim report, nor is it a simple announcement or proxy statement. It is a formal capital/financing update document detailing the issuance and related information. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length (15,000 characters) and detailed financial data support that this is a substantive financing document, not just an announcement or certification.
2025-11-11 Chinese
关于使用闲置自有资金购买理财产品的进展公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Shanxi Jinbo Biopharmaceutical Co., Ltd. regarding the progress of using idle self-owned funds to purchase wealth management products. It details the amounts, types, and terms of the financial products purchased, the authorization and approval process, risk control measures, and related disclosures. The document is a regulatory disclosure about financing activities involving the company's capital management, specifically the use of idle funds for investment in bank wealth management products. It is not a full financial report, audit, or earnings release, nor is it a meeting material or voting result. It fits the category of Capital/Financing Update (CAP) as it provides updates on the company's financing activities and capital usage. The document length is sufficient and contains substantive details about the financing activity, not just a brief announcement or certification, so it is not RPA or RNS.
2025-10-29 Chinese
第四届董事会第十七次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at the 17th meeting of the 4th Board of Directors of Shanxi Jinbo Biopharmaceutical Co., Ltd. It includes details about the meeting's convening, attendance, and voting results on two main agenda items: approval of the company's 2025 Q3 report and the re-election of board committee members. The document references the 2025 Q3 report but does not contain the report itself; instead, it directs readers to the official website for the full report. The document primarily concerns board decisions and changes in board committee composition, which aligns with announcements about board/management information rather than the financial report itself. The document length is short (1521 characters), and it serves as a meeting resolution announcement rather than a full financial or quarterly report. Therefore, the appropriate classification is Board/Management Information (MANG).
2025-10-28 Chinese
2025年三季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled "2025 年第三季度报告" which translates to "2025 Third Quarter Report." It contains detailed financial data including consolidated and parent company balance sheets, income statements, cash flow statements, and explanations of significant changes in financial data. The report covers the period ending September 30, 2025, and includes quarterly financial performance metrics, shareholder information, and notes on significant events during the quarter. The document explicitly states it is a quarterly report and is unaudited. The length of the document (15,000 characters) and the presence of comprehensive financial statements and analysis confirm it is a full interim/quarterly financial report rather than a brief announcement or certification. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). 9M 2025
2025-10-28 Chinese
关于改选部分董事会专门委员会委员的公告
Board/Management Information Classification · 100% confidence The document is an announcement regarding the re-election of members of the company's board specialized committees. It details changes in the composition of the board's strategic, nomination, and remuneration committees. There is no financial data, no mention of annual or quarterly reports, earnings, or other financial disclosures. The focus is on board/management changes specifically related to committee membership. Therefore, this fits the category of Board/Management Information (MANG). The document length and content confirm it is not a brief announcement of a report or a certification, but a substantive announcement of board committee changes.
2025-10-28 Chinese
关于审计机构变更质量控制复核人的公告
Audit Report / Information Classification · 95% confidence The document is an announcement regarding the change of the quality control reviewer within the audit firm appointed for the company's 2025 audit. It details the replacement of the individual responsible for quality control review of the audit work. The document does not contain any financial statements or substantive financial data, nor is it a full audit report. It is a regulatory announcement about audit personnel changes related to the audit process. Therefore, it fits best under 'Audit Report / Information (AR)' as it relates to audit information but is not a full annual report or audit report itself. The document length is short and focused on audit quality control personnel change, which aligns with AR rather than a full Annual Report or Regulatory Filing. FY 2025
2025-10-28 Chinese

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.